Advarra Announces Advarra GPS
Advarra, the provider of institutional review board (IRB), institutional biosafety committee (IBC), research quality and compliance consulting services, and standards-based research technology solutions, announces Advarra GPS-a completely managed service to guide, protect, and streamline research programs for health systems, hospitals, and academic medical centers. Advarra GPS helps institutions navigate the challenges of operating a local IRB office and chart a path to increased efficiency, greater compliance, and overall scalability.
“We continue to offer our institutional partners new services to guide and improve their research programs. Advarra GPS is truly an innovation that demonstrates our commitment to supporting research institutions as they navigate an increasingly complex and challenging landscape,” said Pat Donnelly, CEO of Advarra. “Our commitment to research compliance services for institutions is unwavering. From our recent acquisition of the industry’s leading CTMS, OnCore by Forte, to the launch of Advarra GPS and many innovations to come, the future of research powered by Advarra is exciting. ”
Advarra offers the institutional reach of any independent IRB, serving well over 3,200 research institutions, health systems, and academic medical centers.
“Navigating research regulations and maintaining a local IRB office is complex and costly. Research institutions often seek increased capacity,” said James Riddle, Vice President of Institutional Services at Advarra. “Advarra GPS charts a course to success by providing a roadmap to guide these organizations through compliance risks, protect from staffing challenges, and streamline approval times.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025